Aberrant transcripts of the FHIT gene are expressed in normal and leukaemic haemopoietic cells

被引:14
作者
Carapeti, M
Aguiar, RCT
Sill, H
Goldman, JM
Cross, NCP
机构
[1] Hammersmith Hosp, Imperial Coll Sch Med, Dept Haematol, London W12 0NN, England
[2] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA
[3] Karl Franzens Univ Graz, Dept Internal Med, A-8036 Graz, Austria
关键词
FHIT; FRA3B; loss of heterozygosity; leukaemia; tumour-suppressor gene; 3p14.2;
D O I
10.1038/bjc.1998.547
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Deletions and apparent transcriptional abnormalities of the FHIT gene at 3p14.2 have recently been reported in a wide variety of solid tumours. To determine whether lesions of this gene also occur in leukaemia, we have analysed a total of 97 patients (chronic myeloid leukaemia, CML, in chronic phase or blast crisis, n = 71, de novo acute leukaemia, n = 26) and 16 normal individuals, intact FHIT transcripts from all cases were amplified using RT-PCR. In addition, smaller size bands that were less intense than the full-length products were amplified from several samples from patients with leukaemia and also from normal leucocytes. Sequencing of the small products revealed that they were derived from FHIT transcripts lacking whole exons. Using single-strand conformation polymorphism analysis, no mutations in the coding sequence were detected in any patient, Furthermore, loss of heterozygosity was not seen in any of 36 informative patients at D3S1300 or D3S1481, markers located within the FHIT locus. We conclude that the FHIT gene and other uncharacterized tumour-suppressor genes at 3p14.2 are unlikely to be involved in the pathogenesis of acute leukaemia or progression of CML from chronic phase to blast crisis. Moreover, low-abundance FHIT transcripts that lack whole exons are not specific to malignant cells and should not be taken as evidence of an abnormality in the absence of demonstrable genomic DNA lesions.
引用
收藏
页码:601 / 605
页数:5
相关论文
共 42 条
  • [1] Fhit, a putative tumor suppressor in humans, is a dinucleoside 5',5'''-P-1,P-3-triphosphate hydrolase
    Barnes, LD
    Garrison, PN
    Siprashvili, Z
    Guranowski, A
    Robinson, AK
    Ingram, SW
    Croce, CM
    Ohta, M
    Huebner, F
    [J]. BIOCHEMISTRY, 1996, 35 (36) : 11529 - 11535
  • [2] MOLECULAR ANALYSIS OF THE SHORT ARM OF CHROMOSOME-3 IN SMALL-CELL AND NON-SMALL-CELL CARCINOMA OF THE LUNG
    BRAUCH, H
    JOHNSON, B
    HOVIS, J
    YANO, T
    GAZDAR, A
    PETTENGILL, OS
    GRAZIANO, S
    SORENSON, GD
    POIESZ, BJ
    MINNA, J
    LINEHAN, M
    ZBAR, B
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (18) : 1109 - 1113
  • [3] Bugert P, 1997, GENE CHROMOSOME CANC, V20, P9, DOI 10.1002/(SICI)1098-2264(199709)20:1<9::AID-GCC2>3.0.CO
  • [4] 2-Z
  • [5] Carapeti M, 1997, EUR J HAEMATOL, V58, P346
  • [6] HEREDITARY RENAL-CELL CARCINOMA ASSOCIATED WITH A CHROMOSOMAL TRANSLOCATION
    COHEN, AJ
    LI, FP
    BERG, S
    MARCHETTO, DJ
    TSAI, S
    JACOBS, SC
    BROWN, RS
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1979, 301 (11) : 592 - 595
  • [7] MINIMAL RESIDUAL DISEASE AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOID-LEUKEMIA IN 1ST CHRONIC PHASE - CORRELATIONS WITH ACUTE GRAFT-VERSUS-HOST DISEASE AND RELAPSE
    CROSS, NCP
    HUGHES, TP
    FENG, L
    OSHEA, P
    BUNGEY, J
    MARKS, DI
    FERRANT, A
    MARTIAT, P
    GOLDMAN, JM
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1993, 84 (01) : 67 - 74
  • [8] Druck T, 1997, CANCER RES, V57, P504
  • [9] Fong KM, 1997, CANCER RES, V57, P2256
  • [10] Allelic loss determination in chronic lymphocytic leukemia by immunomagnetic bead sorting and microsatellite marker analysis
    Gartenhaus, RB
    [J]. ONCOGENE, 1997, 14 (03) : 375 - 378